Two lawsuits filed Wednesday in the D.C. Circuit Court of Appeals mark the beginning of a rocky legal road for the Environmental Protection Agency following its reversal of a 2009 rule underpinning ...

SAN FRANCISCO -- One new startup is called Recursive with an "e." Another is called Ricursive with an "i." They are trying to do the same thing: Build artificial intelligence that can improve itself ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Ludi Akue discusses how the tech sector’s ...

According to God of Prompt on Twitter, MIT researchers have introduced a new prompt engineering technique called 'Recursive Meta-Cognition' that enables ChatGPT to reason like a team of experts rather ...

In every musician's career, there are the songs that stand out among the rest. Maybe it's a song they were nervous to share with the world, the song that changed everything, or the song that was ...

Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recent victories by Democratic gubernatorial candidates in New Jersey and Virginia and for seats on the Georgia Public Service Commission have led outlets like Politico to brand the outcomes as the ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...